Melanoma: brain metastases, survival, prognostic factors · Radiosurgery, stereotactic · Temozolomide Summary Aim: We wanted to determine the factors influencing survival in a retrospective review of patients with melanoma brain metastases to permit more specific recommendations regarding therapy. Patients and Methods: We reviewed the data of 100 patients treated at the Department of Dermatology and Radiation Oncology, University of Zurich, and the Klinik im Park, Zurich. Information on potential prognostic factors (age, sex, location of the primary tumor, Clark level, Breslow index, histological type, number of brain metastases, stage at initial diagnosis, location of brain metastases, and therapy) was collected from the medical records of 100 patients treated between 1966 and 2002. Univariate and multivariate analyses were performed to identify significant prognostic factors. Results: The overall median survival time was 4.8 months, with 6-month, 1-year and 2-year survival percentages of 36, 14 and 5%, respectively. Univariate analysis indicated that survival correlated significantly with radiotherapy (partial and whole brain), surgery, stereotactic radiosurgery, chemotherapy, Clark level and Breslow index. Treatment with temozolomide (p = 0.052) and number of brain metastases (p = 0.07) failed to be statistically significant. Multivariate analysis confirmed radiotherapy (partial and whole brain), surgery, stereotactic radiosurgery, chemotherapy and the location of brain metastases as independent and significant prognostic factors of survival. The remaining factors did not reach statistical significance in multivariate analysis. Conclusion: Radiotherapy, chemotherapy and especially surgery and stereotactic radiosurgery seem to significantly prolong survival, as shown by multivariate analysis. Treatment with temozolomide will possibly play an important role in the future management of patients with brain metastases from cutaneous melanoma, but further prospective studies to verify this assumption are urgently needed.
Summary

Aim:
We wanted to determine the factors influencing survival in a retrospective review of patients with melanoma brain metastases to permit more specific recommendations regarding therapy. Patients and Methods: We reviewed the data of 100 patients treated at the Department of Dermatology and Radiation Oncology, University of Zurich, and the Klinik im Park, Zurich. Information on potential prognostic factors (age, sex, location of the primary tumor, Clark level, Breslow index, histological type, number of brain metastases, stage at initial diagnosis, location of brain metastases, and therapy) was collected from the medical records of 100 patients treated between 1966 and 2002. Univariate and multivariate analyses were performed to identify significant prognostic factors. Results: The overall median survival time was 4.8 months, with 6-month, 1-year and 2-year survival percentages of 36, 14 and 5%, respectively. Univariate analysis indicated that survival correlated significantly with radiotherapy (partial and whole brain), surgery, stereotactic radiosurgery, chemotherapy, Clark level and Breslow index. Treatment with temozolomide (p = 0.052) and number of brain metastases (p = 0.07) failed to be statistically significant. Multivariate analysis confirmed radiotherapy (partial and whole brain), surgery, stereotactic radiosurgery, chemotherapy and the location of brain metastases as independent and significant prognostic factors of survival. The remaining factors did not reach statistical significance in multivariate analysis. Conclusion: Radiotherapy, chemotherapy and especially surgery and stereotactic radiosurgery seem to significantly prolong survival, as shown by multivariate analysis. Treatment with temozolomide will possibly play an important role in the future management of patients with brain metastases from cutaneous melanoma, but further prospective studies to verify this assumption are urgently needed.
Introduction
Melanoma has a tendency to metastasize to the brain and is the third most common cause of cerebral metastases in most series, exceeded only by lung and breast primary sites [1] . As a result, brain metastases from melanoma are diagnosed in 6-43% of patients and found in 12-74% of deceased patients [2] . Overall, cerebral metastases indicate a poor prognosis [3] . The natural course without treatment is that of progressive neurological deterioration with a median survival of only a few months. Today, a number of different treatment modalities are available and new agents have been introduced, such as the oral alkylating agent temozolomide. This study was initiated to define independent factors influencing survival in patients with brain metastases from cutaneous melanoma so as to assist clinical decision-making and to help design meaningful prospective randomized studies.
Patients and Methods
The medical records of 100 patients with brain metastases from cutaneous melanoma treated between 1966 and 2002 at the Departments of Dermatology and Radiation Oncology, University of Zurich and the Klinik im Park, Zurich, were retrospectively reviewed. The brain metastases were diagnosed with computed tomography (CT) or magnetic resonance imaging (MRI). In 10 cases, diagnosed between 1966 and 1980, the diagnosis was made based on radioisotope scanning (szintigraphy) and clinical symptoms only. For each patient, age, sex, location of the primary tumor, Clark level, Breslow index, histological type, number of brain metastases, stage at initial diagnosis, location of brain metastases and treatment modality were recorded. For the analysis of prognostic factors, three age cohorts were formed: <40 years, 40-60 years and >60 years. Two groups were formed to describe the location of brain metastases: cerebrum only and cerebrum combined with other locations (cerebellum, brain stem, basal ganglia). Because of the small number of patients with Clark levels I, II and III, these patients were combined in a group and compared to patients with Clark levels IV and V. Some medical records lacked data for all examined factors; the missing data were not considered in the statistical evaluation.
Statistical Methods
Overall survival from the time of diagnosis of brain metastases was calculated with the Kaplan-Meier method. Univariate analyses were performed using the Kaplan-Meier method and log rank tests. Multivariate survival analyses were performed using the Cox proportional hazards model (stepwise backwards method). 8 factors with p < 0.2 in univariate analysis were taken into multivariate analysis (Clark level, number of brain metastases, location of brain metastases, radiotherapy, surgery, radiosurgery, chemotherapy and temozolomide).
Results
Patient Characteristics
A total of 100 patients with brain metastases were evaluated; the median age of the patient cohort at diagnosis of brain metastases was 48.7 years (range: 18-80 years). 36 patients were female and 64 patients were male (table 1). In the majority of patients, the primary tumor was located on the trunk, followed by the upper extremities. The median interval between the diagnosis of the primary tumor and brain metastases was 34 months. In 72% of patients with brain metastases, the primary melanoma reached a Clark level IV or V and in 51% a Breslow index >2.01 mm. 41 patients had a single brain metastasis (42%); 56 patients had multiple lesions. The brain metastases were located in the hemispheres in 78 patients (81%) and were combined with cerebellar, brain stem or basal ganglia metastases in 18 patients. 71% of patients were suffering from extracranial metastases at the time brain metastases were detected, and 17% from lymph node metastases, whereas 12% showed no extracranial metastases. Extracranial metastases were frequently located in the lungs (75%) followed by the liver (49%). All patients were in good physical condition, 90% could be treated in an outpatient setting.
Treatment
All patients received steroids, usually dexamethasone (dose range 8-60 mg/d, mean 14.9 mg/d), which was tapered out slowly and eventually discontinued. 54 patients received radiotherapy of the brain (RT). Of these, 35 patients (65%) were treated with whole brain radiotherapy (WBRT), 12 (22%) with partial brain radiotherapy (PBRT) and 7 (13%) with PBRT followed by WBRT. The total dose for both WBRT and PBRT ranged from 12 to 55 Gy (mean 30.1 Gy). In 17 cases (32%) radiotherapy of the brain was the only therapy, in 20 cases (37%) WBRT was administered after surgery or stereotactic radiosurgery, in 4 cases (7%) WBRT preceded surgery or stereotactic radiosurgery (SRS) and in 13 cases (24%) WBRT was combined with chemotherapy or temozolomide. 37 patients were treated with surgery and 17 patients by SRS (gamma-knife based in 12 cases (71%), linear-accelerator based in 5 cases (29%)). The dose of SRS used ranged from 10 to 22 Gy and was prescribed to the 90, 95 or 100% isodose encompassing the metastasis for patients treated with a linear accelerator. Patients treated with a gamma knife received 20 Gy prescribed at the 50% isodose at the margin of the metastasis. In 13 cases (24%) surgery or SRS were the only treatment, in all other cases these therapies were combined with WBRT and/or chemotherapy. 3 patients received surgery and 3 patients SRS more than once, 4 patients a combination of both. In 30 patients (56%) the brain involvement was solitary. In 4 cases (7%) 2 metastases were treated, in 9 cases (17%) 3 metastases and in 7 cases (13%) more than 3 metastases. In the remaining 4 cases the number of brain metastases was unknown. Chemotherapy was given to 38 patients, the most commonly used agent being DTIC (41%). The number of cycles ranged from 1 to 6 (mean 2.9 cycles) at a starting dosage of 250 mg/m 2 /d in the majority of cases. Other substances used included cisplatine, oncovine, interferon α and CCNU in various combinations. A chemotherapy alone was given in 8 cases (21%). 
Survival
The overall survival of the 100 patients was 36% at 6 months, 14% at 1 year and 5% at 2 years, with a median survival time of 4.8 months.
Prognostic Factors
The factors that predicted improved survival by univariate analysis were the Clark level, Breslow index, radiotherapy (WBRT/PBRT), surgery, SRS and chemotherapy (table 1 and fig. 1 ). Patients with a Breslow index >4 mm survived longest (median 7.6 months) in our study. In an attempt to define the reasons why this group lived longest, χ 2 tests were performed. However, no differences in the patient characteristics could be found between the four groups, with the exception that chemotherapy was administered more frequently in the group with an index >4 mm compared to the group with an index of 2.01-4 mm. Eight factors with p < 0.2 in univariate analysis were analyzed by the multivariate proportional hazards model (Clark level, location of brain metastases, number of brain metastases, radiotherapy, surgery, SRS, chemotherapy, temozolomide). In 37 medical records data for the Clark level were incomplete, reducing the number of patients with a complete set of data for all factors to 63. Therefore, the proportional hazards model was applied twice, including the Clark level in a first analysis and excluding this factor in a second. The results are summarized in table 2. Analyzed factors that are not listed failed to reach statistical significance.
Discussion
It is well known that prognosis following the development of intracranial disease from melanoma is poor. In this survey, the median survival time from diagnosis of cerebral metastases was 4.8 months and only 4 patients lived for more than 2 years. This is consistent with other reports, which quote median overall survival as ranging from 2 to 5 months [4] [5] [6] . Despite this short overall survival, the present study identifies factors that have an impact on survival: radiotherapy (partial and whole brain), surgery, radiosurgery, chemotherapy, and brain metastases located in the hemispheres only. These factors are associated with an improved survival and remain independently and significantly associated with prolonged survival in multivariate analysis, which is also known from the literature [7] [8] [9] [10] . The reported median survival time for patients treated with radiotherapy or chemotherapy ranges from 2 to 4 months [11] [12] [13] , whereas the median survival time for surgery or SRS ranges from 5 to 22 months [14, 15] and from 8 to 22 months [16] [17] [18] , respectively. We found similar ranges for patients treated with surgery or radiosurgery, and slightly longer median survival times for radiotherapy of the brain (WBRT/ PBRT) and chemotherapy (5.5 and 6.6 months, respectively). The combination of WBRT with any form of a local therapy (surgery or radiosurgery) seems to significantly prolong median survival in patients with brain metastases from malignant melanoma independently of the number of metastases [19] . Others could not find a survival advantage for a combined treatment with WBRT and SRS, if only patients with solitary metastases are considered [20] . With regard to the remaining prognostic factors analyzed, the results in other studies vary. All factors tested in this survey have been shown to have statistically significant influence on survival in at least one other study: age [21] , sex [22] , location of the primary tumor [22] , Clark level and Breslow index [23] , histological type [23] , number of brain metastases [6, 10, 18] , and stage at initial diagnosis [6, 13] . Temozolomide therapy missed statistical significance both in univariate and multivariate analysis in this survey. However, significance was only marginally missed (p = 0.052), making it seem reasonable that in a larger study with a higher number of patients, significance might be achieved. A recent study comparing temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma, however without cerebral metastases [24] , demonstrated that temozolomide shows equal efficacy to DTIC. In a further study [25] , an increase of 1.1 months in survival in patients treated with temozolomide compared to patients treated with DTIC was found, although the difference was not statistically significant.
In conclusion, our retrospective study suggests that patients receiving either radiotherapy, surgery, radiosurgery or chemotherapy have a more favorable outlook and achieve prolonged survival. Patients with supratentorially located brain metastases are also likely to survive for a longer period of time. With regard to temozolomide, the results found here propose that temozolomide might become an effective treatment modality in the future. However, since we cannot exclude a bias in the selection of our patient population and in the selection of patients who received surgery or stereotactic radiosurgery, prospective randomized clinical studies are needed which will address these issues.
